Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for hematopoietic reconstitution after allo-HSCT in severe aplastic anemia
ChiCTR2400091592Phase 4Not yet recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hetrombopag in aplastic anemia (2 arms), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoints: Platelet engraftment/recovery, Hemoglobin/red blood cell transfusion independence and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2400091592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091592.